News headlines about BioSpecifics Technologies (NASDAQ:BSTC) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioSpecifics Technologies earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.0056596876551 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several equities analysts have recently issued reports on BSTC shares. HC Wainwright restated a “buy” rating on shares of BioSpecifics Technologies in a research report on Monday, December 11th. Zacks Investment Research upgraded BioSpecifics Technologies from a “sell” rating to a “hold” rating and set a $49.00 target price for the company in a research report on Thursday, December 28th. Finally, BidaskClub upgraded BioSpecifics Technologies from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 24th.
BioSpecifics Technologies stock opened at $43.39 on Friday. The stock has a market cap of $312.37, a PE ratio of 25.52 and a beta of 1.43. BioSpecifics Technologies has a 1 year low of $38.05 and a 1 year high of $58.79.
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.